Markman Advisors
Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged Coherus
Sandoz lost two IPRs challenging Humira® patents - what does this mean for other biosimilars?

Sandoz was denied institution on two IPRs against Humira® patents owned by AbbVie.  As we previously discussed, in late 2017, Sandoz filed eight different IPRs against Humira® patents.  Two of those IPRs just failed to reach institution.  What are the take-aways, for Sandoz and any other Humira® biosimilars?

Read More
Markman AdvisorsAbbVie, Humira, Sandoz, Amgen, Coherus Biosciences, Coherus, IPR, Inter Partes Review, PTAB, patent, formulation, psoriasis Comment
Sandoz’s aBLA for HUMIRA® has been accepted by FDA -- what happens next?

Sandoz, the generic arm of Novartis, has announced that its abbreviated Biologic License Application (aBLA) for a Humira® biosimilar has been accepted by FDA.  Now that Sandoz’s aBLA has been accepted for review by FDA, what happens next on the patent front? 

Read More
Markman AdvisorsSandoz, Novartis, AbbVie, Humira, FDA, aBLA, BPCIA, Coherus, Coherus Biosicences, Boehringer-Ingelheim, patent dance, Enbrel, Neupogen, IPR, inter partes review, patent, biosimilar
Can Coherus invalidate Amgen’s Enbrel® patents?

Amgen’s Enbrel® blockbuster faces encroaching biosimilar competition from Sandoz and Coherus Biosciences.  Coherus Biosciences has filed petitions for inter partes review against Amgen’s two protein patents covering Enbrel®, the ‘182 patent and the ‘522 patent.  The institution decisions are due before the trial:  March 15, 2018 for the ‘182 IPR, and March 13, 2018 for the ‘522 IPR.  If the IPRs are instituted, that could shift the dynamics, and push the parties to agree on an entry date.  What are Coherus's invalidity arguments?

Read More
Markman AdvisorsAmgen, Sandoz, Coherus, Enbrel, IPR, inter partes review, TNF, TNF receptor, IgG, inflammation, inhibitor, PTABComment